Scorecard: Is Your Health Insurer Restricting Access to Prescription Drugs?
New research from Dr. Kenneth E. Thorpe and Manasvini Singh of Emory University sheds light on how leading Michigan-based health insurance plans and pharmacy benefit managers (PBMs) compare with one another in terms of access to medicines for patients with autoimmune diseases. These patients are often among those most commonly subjected to restrictions such as step therapy. In conjunction with the release of this analysis, Let MI Doctors Decide has applied an average “grade” to each of the health plans analyzed across therapeutic areas. Click buttons to read both the study and our accompanying resource so that you can better understand how health plans are impacting patient access to needed treatments.
Step Therapy Explained: Heather’s Story
Meet Heather, a woman who was diagnosed with multiple sclerosis and forced to endure step therapy. Because of the policy, Heather had to wait five months before she could receive the medicine her doctor prescribed.
Click below to watch our video series on step therapy, which includes a roundtable discussion and individual interviews with health care experts.
A recent poll conducted by Lake Research Partners found that seven out of 10 Michigan consumers have an unfavorable view of step therapy. Ninety-eight percent of these consumers believe that doctors rather than insurance companies should have the final say when it comes to treating a patient with an autoimmune disease. Click below to view the full poll results.